Related Experiment Video
Updated: Jul 1, 2026
Method for Whole Mount Antibody Staining in Chick
Published on: February 2, 2009
Development and Characterization of 4A7: A High-Affinity Monoclonal Antibody Targeting Claudin18.2
Yahui Wu1,2, Juan Tian1,2, Yangyihua Zhou2
1Hunan Normal University Health Science Center, Changsha, Hunan Province, People's Republic of China.
Purpose:
Claudin18.2 has emerged as a promising therapeutic target due to its high expression in gastric (GC) and pancreatic cancers (PC). However, patients with advanced, unresectable, or metastatic GC or PC face poor prognoses, highlighting the urgent need for more effective Claudin18.2-targeted therapies.
Methods And Results:
We developed 4A7, a fully human monoclonal antibody with superior affinity and specificity for Claudin18.2, using a rigorous positive and negative screening strategy to eliminate cross-reactivity with Claudin18.1. In vitro, 4A7 demonstrated significantly enhanced binding activity, as well as robust antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), outperforming IMAB362, a clinical investigational antibody. In vivo, 4A7 exhibited remarkable tumor growth inhibition both as a monotherapy and in combination with anti-mPD-1, achieving superior efficacy compared to IMAB362. Additionally, 4A7 demonstrated a higher degree of humanization and comparable stability, supporting its translational potential.
Conclusion:
4A7 shows great promise as a next-generation therapeutic for Claudin18.2-positive cancers, offering improved efficacy and reduced immunogenicity. This study not only highlights 4A7's potential to address unmet clinical needs but also provides a foundation for future innovations in monoclonal antibody-based cancer therapy.
Insights
A novel antibody, 4A7, shows superior efficacy against Claudin18.2-positive gastric and pancreatic cancers. This next-generation therapy offers improved tumor inhibition and reduced immunogenicity for advanced cancer patients.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Claudin18.2 is highly expressed in gastric (GC) and pancreatic cancers (PC).
- Advanced, unresectable, or metastatic GC/PC patients have poor prognoses.
- There is an urgent need for effective Claudin18.2-targeted therapies.
Purpose of the Study:
- To develop and characterize 4A7, a fully human monoclonal antibody targeting Claudin18.2.
- To evaluate 4A7's binding affinity, specificity, and in vitro/in vivo anti-tumor activity.
- To compare 4A7's efficacy and translational potential against the investigational antibody IMAB362.
Main Methods:
- Developed 4A7 using a rigorous screening strategy to ensure Claudin18.2 specificity.
- Assessed in vitro binding, antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP).
- Evaluated in vivo tumor growth inhibition as monotherapy and in combination with anti-mPD-1 in preclinical models.
Main Results:
- 4A7 demonstrated superior binding affinity and specificity for Claudin18.2 compared to IMAB362.
- In vitro, 4A7 showed enhanced ADCC and ADCP.
- In vivo, 4A7 achieved superior tumor growth inhibition, both alone and with anti-mPD-1, compared to IMAB362.
Conclusions:
- 4A7 is a promising next-generation therapeutic for Claudin18.2-positive cancers.
- 4A7 offers improved efficacy and reduced immunogenicity, addressing unmet clinical needs.
- This study supports 4A7's translational potential and future innovations in antibody-based cancer therapy.
More Related Videos
12:15The C. elegans Intestine As a Model for Intercellular Lumen Morphogenesis and In Vivo Polarized Membrane Biogenesis at the Single-cell Level: Labeling by Antibody Staining, RNAi Loss-of-function Analy
Published on: October 3, 2017
09:45Production of Monoclonal Antibodies Targeting Aminopeptidase N in the Porcine Intestinal Mucosal Epithelium
Published on: May 18, 2021
